• NeuroSense outlined an accelerated, lower-cost development plan to move PrimeC toward a potential ALS approval.
• Strategy centers on three shorter studies to support an earlier regulatory submission than a single large confirmatory trial.
• Planned work includes AI-based modeling to quantify PrimeC’s formulation advantage, supporting differentiation and potential added patent protection.
• An active-comparator trial is planned to test PrimeC directly against edaravone to sharpen clinical and commercial positioning.
• Canada track targets a New Drug Submission in December 2026, aiming for earlier access based on existing data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN36856) on August 31, 2026, and is solely responsible for the information contained therein.